A new drug application (NDA) has been submitted to the FDA, seeking approval of rivoceranib in combination with camrelizumab (SHR-1210) for the frontline treatment of patients with unresectable hepatocellular carcinoma (uHCC).1
Please refer to the following website for further details: FDA Approval Sought for Frontline Camrelizumab Plus Rivoceranib in uHCC (targetedonc.com)